These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19799845

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunological markers that correlate with protection immunity against tularemia infection.
    Firstova VV, Mokrievich AN, Pavlov VM, Gorbatov AA, Kombarova TI, Biketov SF, Dyatlov IA.
    Adv Exp Med Biol; 2014; 808():15-23. PubMed ID: 24595607
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.
    Wayne Conlan J, Shen H, Kuolee R, Zhao X, Chen W.
    Vaccine; 2005 Mar 31; 23(19):2477-85. PubMed ID: 15752834
    [Abstract] [Full Text] [Related]

  • 6. Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.
    Rotem S, Cohen O, Bar-Haim E, Bar-On L, Ehrlich S, Shafferman A.
    PLoS One; 2014 Mar 31; 9(1):e85215. PubMed ID: 24400128
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
    Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP.
    Clin Vaccine Immunol; 2009 Apr 31; 16(4):444-52. PubMed ID: 19211773
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.
    Tärnvik A, Eriksson M, Sandström G, Sjöstedt A.
    Immunology; 1992 Jul 31; 76(3):349-54. PubMed ID: 1526645
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung.
    Bar-On L, Cohen H, Elia U, Rotem S, Bercovich-Kinori A, Bar-Haim E, Chitlaru T, Cohen O.
    Vaccine; 2017 Dec 15; 35(50):7001-7009. PubMed ID: 29102170
    [Abstract] [Full Text] [Related]

  • 13. Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination.
    Fuller CL, Brittingham KC, Hepburn MJ, Martin JW, Petitt PL, Pittman PR, Bavari S.
    J Allergy Clin Immunol; 2006 May 15; 117(5):1186-8. PubMed ID: 16675351
    [No Abstract] [Full Text] [Related]

  • 14. Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain.
    Gosselin EJ, Gosselin DR, Lotz SA.
    Hum Immunol; 2005 Oct 15; 66(10):1039-49. PubMed ID: 16386645
    [Abstract] [Full Text] [Related]

  • 15. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
    Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW.
    Vaccine; 2008 Sep 26; 26(41):5276-88. PubMed ID: 18692537
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain.
    Elkins KL, Cowley SC, Bosio CM.
    Microbes Infect; 2003 Feb 26; 5(2):135-42. PubMed ID: 12650771
    [Abstract] [Full Text] [Related]

  • 18. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
    Baron SD, Singh R, Metzger DW.
    Infect Immun; 2007 May 26; 75(5):2152-62. PubMed ID: 17296747
    [Abstract] [Full Text] [Related]

  • 19. Expansion and retention of pulmonary CD4+ T cells after prime boost vaccination correlates with improved longevity and strength of immunity against tularemia.
    Roberts LM, Wehrly TD, Crane DD, Bosio CM.
    Vaccine; 2017 May 02; 35(19):2575-2581. PubMed ID: 28372827
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.